FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079846465> ?p ?o ?g. }

• W2079846465 endingPage "172" @default.
• W2079846465 startingPage "168" @default.
• W2079846465 abstract "International Journal of Palliative NursingVol. 21, No. 4 CommentaryUse of oral formulations of fentanyl for breakthrough cancer painScott Handsaker, Laura Dempsey, Carole FabbyScott HandsakerSearch for more papers by this author, Laura DempseySearch for more papers by this author, Carole FabbySearch for more papers by this authorScott Handsaker; Laura Dempsey; Carole FabbyPublished Online:22 Apr 2015https://doi.org/10.12968/ijpn.2015.21.4.168AboutSectionsView articleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareShare onFacebookTwitterLinked InEmail View article References Bhatnagar S, Devi S, Vinod NK et al. (2014) Safety and Efficacy of Oral Transmucosal Fentanyl Citrate Compared to morphine sulphate immediate release tablet in management of breakthrough cancer pain. Indian Journal of Palliative Care 20(3): 182–7 Crossref, Medline, Google ScholarBornemann-Cimenti H, Wejbora M, Istvan S et al. (2013) Fentanyl for the treatment of tumor related break-through pain. Deutsches Arzteblatt International 110(16): 271–7 Medline, Google ScholarBuchanan A, Davies A (2014) Breakthrough cancer pain: the current situation. Int J Palliat Nurs 20(1): 6–8 Link, Google ScholarDarba J, Kaskens L, Sanchez de la Rosa R (2014) Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain. Clinicoecon Outcomes Res 6: 1–9 Google ScholarDavies A, Zeppetella G, Andersen S et al. (2011) Multicentre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 15(7): 756–63 Crossref, Medline, Google ScholarDavies A, Buchanan A, Zeppetella G et al. (2013) Break-through cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage 46(5): 619–28 Crossref, Medline, Google ScholarGordon D (2006) Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review. Oncol Nurs Forum 33(2): 257–64 Crossref, Medline, Google ScholarGrape S, Schug S, Lauer S, Schug B (2010) Formulations of fentanyl for the management of pain. Drugs 70(1): 57–72 Crossref, Medline, Google ScholarHandsaker S, Dempsey L, Fabby C (2013) Grading clinical guidelines for the use of transmucosal immediate release fentanyl products in breakthrough pain. Int J Palliat Nurs 19(2): 60–5 Link, Google ScholarKuo K, Saokaew S, Strenehjem D (2013) The pharmacoeconomics of breakthrough cancer pain. J Pain Palliat Care Pharmacother 27(2): 167–75 Crossref, Medline, Google ScholarMercadante S, Villari P, Ferrera P et al. (2007) Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic breakthrough pain. Br J Cancer 96(12): 1828–33 Crossref, Medline, Google ScholarMercadante S (2012) Pharmacotherapy for breakthrough cancer pain. Drugs 72(2): 181–90 Crossref, Medline, Google ScholarMercadante S, Porzio G, Aielli F et al. (2013) The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting. Support Care Cancer 21(8): 2335–9 Crossref, Medline, Google ScholarNovotna S, Valentova K, Fricova J et al. (2014) A randomized, placebo controlled study of the new sublingual formulation of fentanyl citrate fentanyl ethypharm for breakthrough pain in opioid treated patients with cancer. Clin Ther 36(3): 357–67 Crossref, Medline, Google ScholarParikh N, Goskonda V, Chavan A et al. (2013) Single dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers a randomized crossover study. Clin Ther 35(3): 236–43 Crossref, Medline, Google ScholarSoden K, Ali S, Alloway L (2010) How do nurses assess and manage breakthrough pain in specialist palliative care inpatient units? A multicenter study. Palliat Med 24(3): 294–8 Crossref, Medline, Google ScholarWebster L, Slevin K, Narayana A et al. (2013) Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioidtolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. Pain Med 14(9): 1332–45 Crossref, Medline, Google Scholar FiguresReferencesRelatedDetails 2 April 2015Volume 21Issue 4ISSN (print): 1357-6321ISSN (online): 2052-286X Metrics History Published online 22 April 2015 Published in print 2 April 2015 Information© MA Healthcare LimitedPDF download" @default.
• W2079846465 created "2016-06-24" @default.
• W2079846465 creator A5004023038 @default.
• W2079846465 creator A5042811555 @default.
• W2079846465 creator A5091316072 @default.
• W2079846465 date "2015-04-02" @default.
• W2079846465 modified "2023-09-30" @default.
• W2079846465 title "Use of oral formulations of fentanyl for breakthrough cancer pain" @default.
• W2079846465 cites W1986133882 @default.
• W2079846465 cites W1987318150 @default.
• W2079846465 cites W2001086017 @default.
• W2079846465 cites W2004417367 @default.
• W2079846465 cites W2012226232 @default.
• W2079846465 cites W2018609304 @default.
• W2079846465 cites W2023222576 @default.
• W2079846465 cites W2026372523 @default.
• W2079846465 cites W2037423289 @default.
• W2079846465 cites W2064720340 @default.
• W2079846465 cites W2089409787 @default.
• W2079846465 cites W2089898760 @default.
• W2079846465 cites W2097740090 @default.
• W2079846465 cites W2135594669 @default.
• W2079846465 cites W2142446315 @default.
• W2079846465 doi "https://doi.org/10.12968/ijpn.2015.21.4.168" @default.
• W2079846465 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25901588" @default.
• W2079846465 hasPublicationYear "2015" @default.
• W2079846465 type Work @default.
• W2079846465 sameAs 2079846465 @default.
• W2079846465 citedByCount "0" @default.
• W2079846465 crossrefType "journal-article" @default.
• W2079846465 hasAuthorship W2079846465A5004023038 @default.
• W2079846465 hasAuthorship W2079846465A5042811555 @default.
• W2079846465 hasAuthorship W2079846465A5091316072 @default.
• W2079846465 hasConcept C121608353 @default.
• W2079846465 hasConcept C126322002 @default.
• W2079846465 hasConcept C141071460 @default.
• W2079846465 hasConcept C159110408 @default.
• W2079846465 hasConcept C17744445 @default.
• W2079846465 hasConcept C199539241 @default.
• W2079846465 hasConcept C23131810 @default.
• W2079846465 hasConcept C2778904085 @default.
• W2079846465 hasConcept C2779473830 @default.
• W2079846465 hasConcept C2779526319 @default.
• W2079846465 hasConcept C2781072394 @default.
• W2079846465 hasConcept C2983098980 @default.
• W2079846465 hasConcept C2991975920 @default.
• W2079846465 hasConcept C2994186709 @default.
• W2079846465 hasConcept C42219234 @default.
• W2079846465 hasConcept C71924100 @default.
• W2079846465 hasConceptScore W2079846465C121608353 @default.
• W2079846465 hasConceptScore W2079846465C126322002 @default.
• W2079846465 hasConceptScore W2079846465C141071460 @default.
• W2079846465 hasConceptScore W2079846465C159110408 @default.
• W2079846465 hasConceptScore W2079846465C17744445 @default.
• W2079846465 hasConceptScore W2079846465C199539241 @default.
• W2079846465 hasConceptScore W2079846465C23131810 @default.
• W2079846465 hasConceptScore W2079846465C2778904085 @default.
• W2079846465 hasConceptScore W2079846465C2779473830 @default.
• W2079846465 hasConceptScore W2079846465C2779526319 @default.
• W2079846465 hasConceptScore W2079846465C2781072394 @default.
• W2079846465 hasConceptScore W2079846465C2983098980 @default.
• W2079846465 hasConceptScore W2079846465C2991975920 @default.
• W2079846465 hasConceptScore W2079846465C2994186709 @default.
• W2079846465 hasConceptScore W2079846465C42219234 @default.
• W2079846465 hasConceptScore W2079846465C71924100 @default.
• W2079846465 hasIssue "4" @default.
• W2079846465 hasLocation W20798464651 @default.
• W2079846465 hasLocation W20798464652 @default.
• W2079846465 hasOpenAccess W2079846465 @default.
• W2079846465 hasPrimaryLocation W20798464651 @default.
• W2079846465 hasRelatedWork W1271824719 @default.
• W2079846465 hasRelatedWork W1998000697 @default.
• W2079846465 hasRelatedWork W2072548073 @default.
• W2079846465 hasRelatedWork W2134802240 @default.
• W2079846465 hasRelatedWork W2412692527 @default.
• W2079846465 hasRelatedWork W2514178786 @default.
• W2079846465 hasRelatedWork W2885819544 @default.
• W2079846465 hasRelatedWork W2941271358 @default.
• W2079846465 hasRelatedWork W4210888970 @default.
• W2079846465 hasRelatedWork W2344404470 @default.
• W2079846465 hasVolume "21" @default.
• W2079846465 isParatext "false" @default.
• W2079846465 isRetracted "false" @default.
• W2079846465 magId "2079846465" @default.
• W2079846465 workType "article" @default.